



**ApopTag[®] Red *In Situ*
Apoptosis Detection Kit**

S7165

**FOR RESEARCH USE ONLY
Not for use in diagnostic procedures**

EMD Millipore Corporation, 28820 Single Oak Drive, Temecula, CA 92590 USA 1-800-437-7500
Technical Support T 1-800-MILLIPORE (1-800-645-4576) F 1-800-437-7502
www.millipore.com

This page left blank intentionally

TABLE OF CONTENTS

I. INTRODUCTION.....	1
Using this Manual	1
Background	1
Principles of the Procedure.....	5
<i>Fig. 1: ApopTag® Methodology</i>	6
Sample Fixation.....	7
Specificity and Reactivity.....	7
Precautions	8
Storage and Shelf Life	9
II. PROTOCOLS	10
Kit Components.....	10
Materials Required But Not Supplied	10
Experimental Preparation and Setup	11
Fluorescent Staining of Paraffin-Embedded Tissue	14
Fluorescent Staining of Tissue Cryosections or Cells	16
III. APPENDIX	19
Reagent Preparation.....	19
Troubleshooting for Microscopy	20
Tech Notes.....	20
#1: Reagents.....	20
#2: Fixatives and fixation.....	20
#3: Reducing time spent performing the protocol.....	21
#4: Methyl green counterstain.....	21
#5: Notes on double-labeling for microscopy	22
#6: Silanized slides.....	22
#7: Required fluorescence filters	22
#8: Containers	23
#9: Plastic coverslips.....	24
<i>Fig. 3: Unit TdT Dilution and Plastic Coverslips Use</i>	24
#10: Controls.....	25
#11: Additional pretreatment procedures	26
#12: Sample handling.....	27
#13: Use of xylene	27
#14: Optional stopping points	27

#15: Morphological confirmation of apoptosis.....	28
#16: Fluorescent counterstains.....	28
#17: Fixation using plastic supports.....	28
Related Products.....	29

IV. REFERENCES 31

Internet Sites.....	31
Publications Cited in Manual.....	31
Publications Citing ApopTag® Kits.....	35
Disclaimers.....	41
Warranty.....	41

I. INTRODUCTION

ApopTag® *In Situ* Apoptosis Detection Kits label apoptotic cells in research samples by modifying genomic DNA utilizing terminal deoxynucleotidyl transferase (TdT) for detection of positive cells by specific staining.

This manual contains information and protocols for the ApopTag® Red Apoptosis Detection Kit (S7165).

Using this Manual

This manual accommodates both the novice and the experienced ApopTag® user. These protocols are presented in a streamlined manner. However, users are directed to sections which provide supplemental information by notations in the protocol. The protocols for all ApopTag® Kits are included in this manual to show the researcher all of the options available for experimental design.

The novice user is advised to read the Introduction, especially the section on sample fixation. Before beginning the protocol, reading the assigned TECH NOTES is recommended. Directions for preparing some of the required reagents can be found in Sec. IV. *Appendix*. Should additional questions arise, assistance is available from Chemicon Technical Service at (800) 437-7500 or at techserv@chemicon.com.

Background

Apoptosis is a form of cell death that eliminates compromised or superfluous cells. It is controlled by multiple signaling and effector pathways that mediate active responses to external growth, survival, or death factors. Cell cycle checkpoint controls are linked to apoptotic enzyme cascades, and the integrity of these and other links can be genetically compromised in many diseases, such as cancer. There are many books in print and hundreds of recent review articles about all aspects of apoptosis (e.g. 7, 11, 19, 24, 39, 42) and the methods for detecting it (e.g. 10, 32, 36).

Of all the aspects of apoptosis, the defining characteristic is a complete change in cellular morphology. As observed by electron microscopy, the cell undergoes shrinkage, chromatin margination, membrane blebbing, nuclear condensation and then segmentation, and division into apoptotic bodies which may be phagocytosed (11, 19, 24). The characteristic apoptotic bodies are short-lived

and minute, and can resemble other cellular constituents when viewed by brightfield microscopy. DNA fragmentation in apoptotic cells is followed by cell death and removal from the tissue, usually within several hours (7). A rate of tissue regression as rapid as 25% per day can result from apparent apoptosis in only 2-3% of the cells at any one time (6). Thus, the quantitative measurement of an apoptotic index by morphology alone can be difficult.

DNA fragmentation is usually associated with ultrastructural changes in cellular morphology in apoptosis (26, 38). In a number of well-researched model systems, large fragments of 300 kb and 50 kb are first produced by endonucleolytic degradation of higher-order chromatin structural organization. These large DNA fragments are visible on pulsed-field electrophoresis gels (5, 43, 44). In most models, the activation of Ca^{2+} -and Mg^{2+} -dependent endonuclease activity further shortens the fragments by cleaving the DNA at linker sites between nucleosomes (3). The ultimate DNA fragments are multimers of about 180 bp nucleosomal units. These multimers appear as the familiar "DNA ladder" seen on standard agarose electrophoresis gels of DNA extracted from many kinds of apoptotic cells (e.g. 3, 7, 13, 35, 44).

Another method for examining apoptosis via DNA fragmentation is by the TUNEL assay, (13) which is the basis of ApopTag[®] technology. The DNA strand breaks are detected by enzymatically labeling the free 3'-OH termini with modified nucleotides. These new DNA ends that are generated upon DNA fragmentation are typically localized in morphologically identifiable nuclei and apoptotic bodies. In contrast, normal or proliferative nuclei, which have relatively insignificant numbers of DNA 3'-OH ends, usually do not stain with the kit. ApopTag[®] Kits detect single-stranded (25) and double-stranded breaks associated with apoptosis. Drug-induced DNA damage is not identified by the TUNEL assay unless it is coupled to the apoptotic response (8). In addition, this technique can detect early-stage apoptosis in systems where chromatin condensation has begun and strand breaks are fewer, even before the nucleus undergoes major morphological changes (4, 8).

Apoptosis is distinct from accidental cell death (necrosis). Numerous morphological and biochemical differences that distinguish apoptotic from necrotic cell death are summarized in the following table (adapted with permission from reference 39).

Table 1: Types of Cell Death: Differential Characteristics

Apoptosis	Necrosis
Morphologic Criteria	
Deletion of single cells	Death of cell groups
Membrane blebbing, but no loss of integrity	Loss of membrane integrity
Cells shrink, ultimately forming apoptotic bodies	Cells swell and lyse
No inflammatory response	Significant inflammatory response
Phagocytosis by adjacent normal cells, and some macrophages	Phagocytosis by macrophages
Lysosomes intact	Lysosomal leakage
Compaction of chromatin into uniformly dense masses	Clumpy, ill-defined aggregation of chromatin
Biochemical Criteria	
Onset tightly regulated by physiological homeostasis	Onset incidental to nonphysiological trauma
Specific enzyme cascades for signal transduction and execution	Enzyme cascades altered or inactive
Metabolically viable during execution	Non-viable during execution
Macromolecules may be newly synthesized	Macromolecules not synthesized
Phosphatidyl serine exposure signals death	Nonspecific lytic effusion indicates death
Nonrandom, oligonucleosomal fragment lengths (DNA ladder)	Random DNA fragment lengths (DNA smear)

ApopTag[®] *In Situ* Apoptosis Detection Kits distinguish apoptosis from necrosis by specifically detecting DNA cleavage and chromatin condensation associated with apoptosis. However, there may be some instances where cells exhibiting necrotic morphology may stain lightly (14, 29) or, in rare instances, DNA fragmentation can be absent or incomplete in induced apoptosis (11). It is, therefore, important to evaluate ApopTag[®] staining results in conjunction with morphological criteria. Visualization of positive ApopTag[®] results should reveal focal *in situ* staining inside early apoptotic nuclei and apoptotic bodies. This positive staining directly correlates with the more typical biochemical and morphological aspects of apoptosis.

Since an understanding of cell morphology is critical for data interpretation and because of the potential for experimentally modifying or overcoming normal apoptotic controls, the following strategy is advised. When researching a new system, the staging and correlation of apoptotic morphology and DNA fragmentation should be characterized. In some tissues, cytoplasmic shrinkage may be indicated by a clear space surrounding the cell. The nuclear morphology of positive cells should be carefully observed at high magnification (400x-1000x). Early staged positive, round nuclei may have observable chromatin margination. Condensed nuclei of middle stages, and apoptotic bodies, usually are stained. Apoptotic bodies may be found either in the extracellular space or inside of phagocytic cells. It is highly recommended that less experienced observers should refer to illustrations of dying cells for comparison with new data (e.g. 11, 19, 24).


An additional, although far less sensitive, method of confirming ApopTag[®] staining results is the detection of DNA fragmentation on agarose gels. If a large percent of the cells in the tissue are apoptotic, then electrophoresis of extracted total genomic DNA and standard dye staining can be used to corroborate the *in situ* staining. However, the single-cell sensitivity of ApopTag[®] histochemistry is far higher than this method. DNA laddering data of comparable sensitivity may be obtained in several other ways. These include methods for selectively extracting the low molecular weight DNA (15), for preparing radiolabeled DNA (30, 40) in combination with resin-bed purification of DNA (12), and for DNA amplification by PCR (35).

The *in situ* staining of DNA strand breaks detected by the TUNEL assay and subsequent visualization by light microscopy gives biologically significant data about apoptotic cells which may be a small percentage of the total population (13, 16). Apoptotic cells stained positive with ApopTag® Kits are easier to detect and their identification is more certain, as compared to the examination of simply histochemically stained tissues. Another feature of ApopTag® is that quantitative results can be obtained using flow cytometry, since end-labeling methodology detects apoptotic cells with a >10-fold higher sensitivity than necrotic cells (14,17). In addition, the occurrence of DNA fragmentation with regard to the cell cycle phase of apoptotic cells can be examined using the TUNEL assay and flow cytometry (16,18).

Principles of the Procedure

The reagents provided in all ApopTag® Kits are designed to label the free 3'OH DNA termini *in situ* with chemically labeled and unlabeled nucleotides. The nucleotides contained in the Reaction Buffer are enzymatically added to the DNA by terminal deoxynucleotidyl transferase (TdT) (13, 31). TdT catalyzes a template-independent addition of nucleotide triphosphates to the 3'-OH ends of double-stranded or single-stranded DNA. The incorporated nucleotides form an oligomer composed of digoxigenin or fluorescein nucleotide and unlabeled nucleotide in a random sequence. The ratio of labeled to unlabeled nucleotide in ApopTag® Kits is optimized to promote anti-digoxigenin antibody binding, or to minimize fluorescein self-quenching. The exact length of the oligomer added has not been measured.

Figure 1: ApopTag[®] Methodology



The ApopTag[®] system differs significantly from previously described *in situ* labeling techniques for apoptosis (13, 16, 38, 46), in which avidin binding to cellular biotin can be a source of error. The digoxigenin/anti-digoxigenin system has been found to be equally sensitive to avidin/biotin systems (22). The sole natural source of digoxigenin is the digitalis plant. Immunochemically-similar ligands for binding of the anti-digoxigenin antibody are generally insignificant in animal tissues, ensuring low background staining. Affinity purified sheep polyclonal antibody is the specific anti-digoxigenin reagent used in ApopTag[®] Kits. This antibody exhibits <1% cross-reactivity with the major vertebrate steroids. In addition, the Fc portion of this antibody has been removed by proteolytic digestion to eliminate any non-specific adsorption to cellular Fc receptors.

Results using ApopTag[®] Kits have been widely published (see Sec. V. *References, Publications Citing ApopTag[®] Kits*). The ApopTag[®] product line provides various options in experimental design. A researcher can choose to detect staining by brightfield or fluorescence microscopy or by flow cytometry, depending on available expertise and equipment. There are also opportunities to study other proteins of interest in the context of apoptosis when using ApopTag[®] Kits. By using antibodies conjugated with an enzyme other than peroxidase and

an appropriate choice of substrate, it is possible to simultaneously examine another protein and apoptosis using ApopTag® Peroxidase Kits. There is also a choice of fluorophores (fluorescein and rhodamine) using ApopTag® technology. Flexibility exists in choosing antibody-fluor combinations to study other important proteins.

Sample Fixation

Use of a cross-linking fixative is believed to tether the small chromatin fragments to the tissue, so that they will not be extracted during the processing steps. The preferred fixative for embedding tissue in paraffin for ApopTag® analysis is standard 10% (v:v) neutral buffered formalin. This kit produces excellent results on formalin-fixed, paraffin-embedded tissue. See Sec. IV. *Appendix, TECH NOTE #2: Fixatives and fixation.*

Formalin-fixed tissue can be embedded in paraffin or in plastic resin (27). Tissue processing in paraffin could increase the number of apparent apoptotic events, and decrease the background, in comparison to cryosections of the same tissue.

Pretreatment of paraffin-embedded tissue sections is required, after rehydration, to improve the exposure of DNA by digesting DNA-binding proteins. The tissue type and the fixation time used can affect the strength of protease pretreatment needed. See Sec. IV. *Appendix, TECH NOTE #11: Additional pretreatment procedures.*

Specificity and Reactivity

Indirect ApopTag® Kits (S7100, S7101, S7110, S7111 and S7165) have been qualified for use in histochemical and cytochemical staining of the following specimens: formalin-fixed, paraffin-embedded tissues, cryostat sections, cell suspensions, cytopins, and cell cultures. Whole mount-methods have been developed (34, 45).

ApopTag® Peroxidase Kits staining specificity has been demonstrated by Chemicon and many other laboratories. Chemicon has tested many types of model cell and tissue systems, including: (a) human prostate, thymus, and large intestine (in-house data); (b) rat ventral prostate post-castration (21), (c) rat thymus lymphocytes treated *in vitro* with dexamethasone (3, 13), (d) 14-day mouse embryo limbs (1) and (e) rat mammary gland in regression after weaning (36). In the thymocyte and prostate models, agarose gel electrophoresis was used to assess the amount of DNA laddering, which peaked coincidentally with

the maximum percentage of stained cells. Numerous journal publications from laboratories worldwide have established the usefulness of ApopTag® Kits. (See Sec. V. *References, Publications Citing ApopTag® Kits*).

ApopTag® Fluorescein and Rhodamine Kits have been tested for specific staining in these model systems: (a) human normal peripheral blood lymphocytes induced with dexamethasone as stained in cytopins, (b) rat regressing mammary gland as stained in formalin-fixed, paraffin-embedded sections, and (c) human leukemic peripheral blood lymphocytes induced with camptothecin, as stained in cell suspensions and used for quantitative flow cytometry (22).

In some instances, certain tissues contain cell types which bind any fluorescein labeled nucleotide such as that contained in the ApopTag® Fluorescein Direct Kit (S7160). It is therefore recommended that this kit (S7160) be used to stain cell suspensions, cytopins and cell cultures, but not tissue sections. Chemicon suggests the use of the ApopTag® Fluorescein Kits (S7110, S7111) or the ApopTag® Red Kit for staining tissue sections.

Precautions

1. The following kit components contain potassium cacodylate (dimethylarsinic acid) as a buffer: Equilibration Buffer (90416), Reaction Buffer (90417), and TdT Enzyme (90418). These components are harmful if swallowed; avoid contact with skin and eyes (wear gloves, glasses) and wash areas of contact immediately.
2. Antibody Conjugate (90429) and Blocking Solution (90425) contain 0.08% sodium azide as a preservative.
3. TdT Enzyme (90418) contains glycerol and will not freeze at -20°C. For maximum shelf life, do not warm this reagent to room temp. before dispensing.

Storage and Shelf Life

1. Store the kit at -15°C to -25°C until the first use. After the first use, if the kit will be used within three months, store the TdT Enzyme (90418) at -15°C to -25°C and store the remaining components at 2°C to 8°C .
2. Protect the anti-digoxigenin rhodamine antibody (90429) from unnecessary exposure to light.

III. PROTOCOL

Kit Components

Table 2: S7165 ApopTag® Red For Indirect Immunofluorescence Staining

Component	Part #	Vol/Qty	Storage
Equilibration Buffer	90416	3.0 mL	-15°C to -25°C
Reaction Buffer	90417	2.0 mL	-15°C to -25°C
TdT Enzyme	90418	0.64 mL	-15°C to -25°C
Stop/Wash Buffer	90419	20 mL	-15°C to -25°C
Blocking Solution	90425	2.6 mL	-15°C to -25°C
Anti-Digoxigenin-Rhodamine*	90429	2.1 mL	2°C to 8°C
Plastic Coverslips	90421	100 ea.	Room Temp.

**affinity purified sheep polyclonal antibody*

Number of tests per kit: Sufficient materials are provided to stain 40 tissue specimens of approximately 5 cm² each when used according to instructions. Reaction Buffer will be fully consumed before other reagents when kits are used for slide-mounted specimens.

Materials Required But Not Supplied

Solvents and Media

- a. Deionized water (dH₂O)
- b. Xylene
- c. Ethanol: absolute, 95%, 70%, diluted in dH₂O
- d. Ethanol: acetic acid, 2:1 (v:v) (for tissue cryosection or cells protocols)
- e. Slide mounting medium (Antifade)

Solutions

- a. 1% paraformaldehyde in PBS, pH 7.4 (methanol-free formaldehyde for tissue cryosections or cells). See Sec. IV. *Appendix, TECH NOTE #2: Fixatives and fixation.*
- b. 10% (v:v) neutral buffered formalin (for fixation before paraffin-embedding). See Sec. IV. *Appendix, TECH NOTE #2: Fixatives and fixation.*
- c. PBS (50 mM sodium phosphate, pH 7.4, 200 mM NaCl)
- d. Protein Digesting Enzyme or Proteinase K, Catalog No. 21627, (for paraffin-embedded tissue protocol).
- e. 0.5-1.0 µg/mL Propidium Iodide in Antifade (S7112)
- f. 0.5-1.0 µg/mL DAPI (4'-6' diamino-2-phenylindole) in Antifade (S7113)

Materials

- a. Silanized glass slides
- b. Glass coverslips (for oil immersion objective, use 22 x 50 mm)
- c. Adjustable micropipettors
- d. Glass or plastic coplin jars
- e. Forceps for handling plastic coverslips (optional)
- f. Humidified chamber
- g. 37°C covered water bath, or incubator at 37°C

Equipment

Light microscope equipped with brightfield optics (40x and 10x objectives) and also equipped for fluorescence. See Sec. IV. *Appendix, TECH NOTE #6: Required fluorescence filters.*

Experimental Preparation and Setup

Note: Protect the fluorescent anti-digoxigenin rhodamine antibody (90429) from unnecessary exposure to light.

Reagent Volumes

The following are suggested volumes of the reagents that will ensure adequate coverage of the specimen:

Table 3: Recommended Reagent Volumes

Reagent	Vol/cm ²	Vol/5 cm ²
Equilibration Buffer	13 µL	65 µL
Working Strength TdT	11 µL	55 µL
Anti-Digoxigenin-Rhodamine	13 µL	65 µL

Working Strength TdT Enzyme

The concentrated TdT Enzyme provided in this kit is supplied in a stabilization buffer to preserve activity. It must be diluted with Reaction Buffer prior to use. Mix reagents in a ratio of 70% Reaction Buffer to 30% TdT Enzyme. To prepare, add in a fresh microcentrifuge tube:

77 µL	Reaction Buffer (90417)
33 µL	TdT Enzyme (90418)
<hr/>	
110 µL	Total

Mix well by vortexing. This reagent may be prepared in advance and stored on ice for no more than 6 hours. This amount is sufficient to treat two 5 cm² tissue specimens.

Note: Use of excessive Working Strength TdT will result in fewer tests per kit.

Protein Digesting Enzyme or Proteinase K

Dilute the 200 µg/mL stock of Proteinase K (Catalog No. 21627) to 20 µg/mL in PBS just before use.

Coplin jar

If this step is to be performed in a coplin jar, adding 3.9 mL of the 200 µg/mL stock Proteinase K (Catalog No. 21627) to 35 mL of PBS will give sufficient volume of the appropriate dilution.

Direct slide application

If this step is to be done directly on the slide, 60 µL of diluted stock is required per 5 cm² specimen.

Working Strength Stop/Wash Buffer

Prepare working strength Stop/Wash Buffer by adding:

1 mL	Stop/Wash Buffer (90419)
34 mL	dH ₂ O
<hr/>	
35 mL	Total

This amount is sufficient to treat 5 slides in a coplin jar. This reagent may be prepared in advance and stored in a glass or plastic container at 4°C for up to 1 year. Use a fresh aliquot for each experiment.

Working Strength Rhodamine Antibody Solution

The concentrated fluorescent antibody is supplied in a stabilization buffer to preserve activity and must be diluted with Blocking Solution prior to use. To prepare in the required ratio, add in a fresh microcentrifuge tube:

68 µL (53% v:v)	Blocking Solution (90425)
62 µL (47% v:v)	Anti-Digoxigenin Conjugate (90429)
<hr/>	
130 µL	Total

Mix well by vortexing and keep on ice. Avoid exposure to light. This reagent may be prepared in advance and stored on ice for no more than 3 hours. This amount is sufficient to treat two 5 cm² tissue specimens.

Nuclear Counterstain with DAPI

DAPI is used with rhodamine. The brightness of the counterstain should be equal to or less than that of the rhodamine. The apparent ratio will depend upon multiple factors. A general purpose concentration of the stain is in the range of 0.5-1 µg/mL in Antifade. For less intense initial counterstaining, these can be diluted by mixing with 2-4 parts Antifade. DAPI counterstain can be removed from chromatin (destained) by extensive washing in PBS. See Sec. IV. *Appendix, TECH NOTE #6: Required fluorescence filters and TECH NOTE #15: Fluorescent counterstains.*

Plastic Coverslips

The purpose of the plastic coverslips is to spread reagents evenly by capillary action over a defined area. They can be omitted for a faster protocol. If the basic coverslip method described in TECH NOTE #8 will be used, note that each plastic coverslip must be cut to a size of ~5 cm² prior to use. Volumes of reagents that sufficiently cover a 5 cm² specimen are also appropriate when using a ~5 cm² coverslip. Refer to TECH NOTE #8 for suggestions as to when the use of coverslips is appropriate in the protocol.

Humidified Container

See Sec. IV. *Appendix, TECH NOTE #7: Containers.*

Length of Assay

Allow for a total processing time of about 3.5 hours. With paraffin sections, or 2.5 hours with tissue cryosections or cultured cells.

Fluorescent Staining of Paraffin-Embedded Tissue

It is recommended that the following sections be read prior to beginning this procedure:

TECH NOTE #4: *double-labeling methods*
TECH NOTE #6: *fluorescence filters*
TECH NOTE #8: *plastic coverslips*
TECH NOTE #9: *controls*
TECH NOTE #10: *other pretreatments*
TECH NOTE #11: *sample handling*
TECH NOTE #12: *xylene*
TECH NOTE #13: *optional stopping points*

DO NOT ALLOW SAMPLES TO DRY OUT DURING PROCESSING.

1. Deparaffinize Tissue Section (in a coplin jar)

- a. Wash the specimen in 3 changes of XYLENE for 5 minutes each wash.
- b. Wash the specimen in 2 changes of ABSOLUTE ETHANOL for 5 minutes each wash.
- c. Wash the specimen once in 95% ETHANOL and once in 70% ETHANOL for 3 minutes each wash.
- d. Wash the specimen in 1 change of PBS for 5 minutes.

2. Pretreat Tissue

- a. Apply freshly diluted PROTEIN DIGESTING ENZYME or PROTEINASE K (20 $\mu\text{g}/\text{mL}$) to the specimen for 15 min. at room temp. in a coplin jar or directly on the slide.
- b. Wash the specimen in 2 changes of PBS in a coplin jar for 2 minutes each wash.

3. Apply Equilibration Buffer

- a. Gently tap off excess liquid and carefully blot or aspirate around the section.
- b. Immediately apply 75 $\mu\text{L}/5 \text{ cm}^2$ EQUILIBRATION BUFFER directly on the specimen.
- c. Incubate for at least 10 seconds at room temp. Refer to TECH NOTE #13: *Optional stopping points*.

4. Apply Working Strength TdT Enzyme

- a. Gently tap off excess liquid and carefully blot or aspirate around the section.
- b. Immediately pipette onto the section 55 $\mu\text{L}/5 \text{ cm}^2$ of WORKING STRENGTH TdT ENZYME.
- c. Incubate in a humidified chamber at 37°C for 1 hour.

5. Apply Stop/Wash Buffer

- a. Put the specimen in a coplin jar containing WORKING STRENGTH STOP/WASH BUFFER, agitate for 15 seconds, and incubate for 10 minutes at room temp.
- b. Remove an aliquot of ANTI-DIGOXIGENIN CONJUGATE from the stock vial sufficient to process the desired number of specimens. Warm the aliquot to room temp. while avoiding exposure to light.

6. Apply Working Strength ANTI-DIGOXIGENIN CONJUGATE

- a. Wash the specimen in 3 changes of PBS for 1 minute each wash.
- b. Gently tap off excess liquid and carefully blot or aspirate around section.
- c. Apply warmed (room temp.) working strength ANTI-DIGOXIGENIN CONJUGATE (rhodamine) to the slide; use about 65 $\mu\text{L}/5 \text{ cm}^2$ of surface covered.

d. Incubate in a humidified chamber for 30 minutes at room temp. Avoid exposure to light.

7. Wash in PBS

a. Wash the specimen in 4 changes of PBS in a coplin jar for 2 minutes per wash at room temp.

8. Counterstain and Mount After Rhodamine Staining

Note: *If double-labeling with immunohistochemistry, use Antifade.*

a. Apply a mounting medium containing 0.5-1 µg/mL of DAPI. Use 15 µL for a 22 x 50 mm coverslip for use with an oil immersion objective.

b. Mount under a glass coverslip.

c. If storage is required, apply rubber cement to edges of the coverslip. Store at -20°C in the dark.

9. View Rhodamine and Counterstain

View by fluorescence microscopy using appropriate excitation and emission filters. See Sec. IV. *Appendix, TECH NOTE #6: Required fluorescence filters* and *TECH NOTE #15: Fluorescent counterstains*.

Fluorescent Staining of Tissue Cryosections or Cells

Note: *Apoptosis in adherent cell cultures can involve detachment from the substrate, and supernatants should be tested, if possible, by using cytospin processing.*

It is recommended that the following sections be read prior to beginning this procedure:

TECH NOTE #4: *double-labeling methods*

TECH NOTE #6: *fluorescence filters*

TECH NOTE #8: *plastic coverslips*

TECH NOTE #9: *controls*

TECH NOTE #10: *other pretreatments*

TECH NOTE #11: *sample handling*

TECH NOTE #12: *xylene*

TECH NOTE #13: *optional stopping points*

DO NOT ALLOW SAMPLES TO DRY OUT DURING PROCESSING.

1. Fix Specimen According to Type

Tissue Cryosections or Adherent Cultured Cells

- a. Fix in 1% PARAFORMALDEHYDE in PBS, pH 7.4 in a coplin jar (or cell culture vessel) preferably for 10 minutes at room temp. or for up to 15 hours at 4°C. Drain off excess liquid. See Sec. IV. *Appendix, TECH NOTE #2: Fixation and fixatives.*
- b. Wash in 2 changes of PBS for 5 minutes each wash.
- c. Post-fix in precooled ETHANOL:ACETIC ACID 2:1 for 5 minutes at -20°C in a coplin jar. Drain, but do not allow to dry (this solvent permeabilizes cells).
- d. Wash in 2 changes of PBS for 5 minutes each wash. Skip to Step 2.

Cell Suspensions for Microscopy

- a. Fix the cells at a density of approximately 5×10^6 cells/mL in freshly diluted 1% PARAFORMALDEHYDE in PBS, pH 7.4 for 10 minutes at room temp. See Sec. IV. *Appendix, TECH NOTE #2: Fixation and fixatives.*
- b. Dry 50-100 μ L of cell suspension on a microscope slide (optionally, cytopsin cells).
- c. As primary cell isolates may be less easily permeabilized than cultured cells, the use of an ETHANOL:ACETIC ACID post-fix step is recommended.
- d. Wash in 2 changes of PBS for 5 minutes each wash. Go to Step 2.

2. Apply Equilibration Buffer

- a. Gently tap off excess liquid and carefully blot or aspirate around the section.
- b. Immediately apply 75 μ L/5 cm^2 of EQUILIBRATION BUFFER directly on the specimen.
- c. Incubate for at least 10 seconds at room temp. Refer to TECH NOTE #13: *Optional stopping points.*

3. Apply Working Strength TdT Enzyme

- a. Gently tap off excess liquid and carefully blot or aspirate around the section.

- b. Immediately pipette onto the section 55 $\mu\text{L}/5 \text{ cm}^2$ of WORKING STRENGTH TdT ENZYME.
- c. Incubate in a humidified chamber at 37°C for 1 hour.

4. Apply Stop/Wash Buffer

- a. Put the specimen in a coplin jar containing WORKING STRENGTH STOP/WASH BUFFER, agitate for 15 seconds, and incubate for 10 min. at room temp.
- b. Remove an aliquot of ANTI-DIGOXIGENIN CONJUGATE from the stock vial sufficient to process the desired number of specimens. Warm the aliquot to room temp. while avoiding exposure to light.

5. Apply Working Strength Anti-Digoxigenin Conjugate

- a. Wash the specimen in 3 changes of PBS for 1 minute each wash.
- b. Gently tap off excess liquid and carefully blot or aspirate around the section.
- c. Apply warmed (room temp.) working strength ANTI-DIGOXIGENIN CONJUGATE (rhodamine) to the slide; use about 65 $\mu\text{L}/5 \text{ cm}^2$ of specimen surface area.
- d. Incubate in a humidified chamber for 30 minutes at room temp. Avoid exposure to light.

6. Wash in PBS

- a. Wash the specimen in 4 changes of PBS in a coplin jar for 2 minutes per wash at room temp.

7. Counterstain and Mount After Rhodamine Staining

Note: *If double-labeling with immunohistochemistry, use Antifade.*

- a. Apply a mounting medium containing 0.5-1 $\mu\text{g}/\text{mL}$ of DAPI. Use 15 μL for a 22 x 50 mm coverslip for use with an oil immersion objective.
- b. Mount under a glass coverslip.
- c. If storage is required, apply rubber cement to edges of coverslip. Store at -20°C in the dark.

8. View Rhodamine and Counterstain

View by fluorescence microscopy using standard fluorescein or rhodamine excitation and emission filters. See Sec. IV. *Appendix, TECH NOTE #6: Required fluorescence filters* and *TECH NOTE #15: Fluorescent counterstains*.

III. APPENDIX

Reagent Preparation

1. 10% Neutral Buffered Formalin

Combine 10 mL of commercial formalin solution and 90 mL PBS, pH 7.4. See Sec. IV. *Appendix, TECH NOTE #2: Fixatives and fixation*.

2. 1% Paraformaldehyde

Combine 1 mL of paraformaldehyde (methanol-free) and 15 mL of PBS, pH 7.4. See Sec. IV. *Appendix, TECH NOTE #2: Fixatives and fixation*.

3. 10X Phosphate Buffered Saline, pH 7.4 (PBS)

To make 1 L, dissolve the following in 800 mL dH₂O:

Na ₂ HPO ₄	55.0 g
NaH ₂ PO ₄	13.5 g
NaCl	117.0 g

Adjust the pH to 7.4 using NaOH or HCl and add dH₂O to a final volume of 1000 mL.

4. PBS + 1% (w:v) BSA

Dissolve 1 g of BSA in PBS, pH 7.4, for a final volume of 100 mL.

5. 10 mM citrate pH 6.0

Combine 294 mg of C₆H₅Na₃O₇•2H₂O and 80 mL of dH₂O. Adjust the pH to 6.0 and add dH₂O to a final volume of 100 mL.

6. DN buffer (30 mM Tris Base, pH 7.2, 4 mM MgCl₂, 0.1 mM DTT)

a. Prepare 1 M Tris base, pH 7.2. Dissolve 12.1 g of Tris base in 80 mL of dH₂O. Adjust the pH to 7.2 with concentrated HCl and add dH₂O to a final volume of 100 mL.

b. Prepare 1.0 M MgCl₂. Dissolve 20.3 g of MgCl₂•6H₂O in sufficient dH₂O for a final volume of 100 mL.

- c. Prepare DN buffer. Combine 3 mL of 1.0 M Tris, pH 7.2, 400 μ L of 1.0 M MgCl₂, 1.54 mg of DTT and sufficient dH₂O for a final volume of 100 mL.

Troubleshooting for Microscopy

Tech Notes

TECH NOTE #1: Reagents

- Reagent temperature:
 - a. Do not warm the stock reagents before dispensing them from containers.
 - b. After dilution, warm the reagents or mixtures to room temperature just before application to the specimen.
- TdT enzyme viscosity:

Pipette TdT more slowly because of its viscosity, when removing the reagent from a container.

TECH NOTE #2: Fixatives and fixation

- Commercial formalin solution contains about 37% (w:v) formaldehyde with 10-15% methanol added as a stabilizer. A standard 1:10 (v:v) dilution of formalin in buffered solution, conventionally called “10% neutral buffered formalin” (NBF), actually contains about 3.7% formaldehyde (w:v). This is the preferred fixative before paraffin-embedding. An aged NBF solution contains impurities that are associated with harsher tissue fixation, as compared to a freshly prepared solution.
- Pure formaldehyde is prepared from solid paraformaldehyde polymer by hydrolysis in water to monomeric formaldehyde. It is then stabilized by packaging in sealed ampules under nitrogen. For example, a 1% (w:v) solution equals a 1:16 dilution of methanol-free, 16% (w:v) formaldehyde in PBS, pH 7.4. This is the preferred fixative for cell suspensions and cultured cells (for either microscopy or flow cytometry).
- Fixation in Bouin’s, Carnoy’s and Histo-Choice fixatives might increase background and are not preferred methods of treatment (41). The recommended procedure for fixing tissue for paraffin-embedding is incubation in neutral buffered formalin from 1 hour to 24 hours at 4°C. Fixation times exceeding 3-5 weeks could decrease the assay sensitivity (9).

Although no quantitative change in staining is apparent from delaying the tissue fixation by holding tissue pieces at 4°C for 18 hours in PBS, immediate fixation is recommended.

- Effects of different fixations and pretreatments for use on single cells were described by A. Negoescu, et al (28a) and by F. Labat-Moleur, et al (28b).

TECH NOTE #3: Reducing time spent performing the protocol

- For a faster protocol, after pretreatment and quenching, specimens can be washed in deionized water. This will remove the need to wash with Equilibration Buffer before labeling with TdT and will give comparable results with most samples.

TECH NOTE #4: Notes on double-labeling for microscopy

- TdT end-labeling has been used in combination with an *in situ* hybridization assay. In this method, hybridization was done following TdT labeling (45).
- Apoptosis cytochemistry can be used together with immunochemical proliferation markers, including halodeoxyuridine labeling of DNA (23, 27) or Ki67/MIB1 (unpublished data). The antigen should be tested for susceptibility to proteinase K, and if this lowers the immunoreactivity, another pretreatment should be tested. Perform thermal tissue treatment before using ApopTag[®]. See Sec. IV. Appendix, *TECH NOTE #10: Other pretreatments*. Use of red and blue enzyme substrates for alkaline phosphatase can give good color contrast.
- A double-labeling fluorescence technique is possible. Choose a fluorescent detection system for an antibody that recognizes an antigen of interest, which provides good contrast with fluorescein or rhodamine.

TECH NOTE #5: Silanized slides

- In order to avoid detachment of tissue sections during processing, we highly recommend the use of silanized glass slides.

TECH NOTE #6: Required fluorescence filters

(Also see *TECH NOTE #15: Fluorescent counterstains*).

- For (Immuno) fluorescence microscopy
 - a. Both the FITC signal and the Propidium Iodide (PI) counterstain can be viewed with a “long pass” filter for FITC (ex. 490 nm & em. 520 nm); this filter allows sufficient PI signal to “bleed through”. A “dual pass” filter, designed for viewing both FITC and PI, would allow more red light through, possibly competing with and decreasing the FITC signal.

As PI binds reversibly to DNA, a PI signal can be modulated up or down by washing the sample and reapplying PI at another concentration.

- b. When visualizing a rhodamine signal and DAPI counterstain, Rhodamine can be viewed with one filter (ex. 540nm & em. 550 nm) and DAPI with another (ex. 365 nm & em. 480 nm). Otherwise, one can use a “triple-bandpass” filter designed to simultaneously view FITC, Texas Red and DAPI.
 - c. Photobleaching will cause the signal to fade in proportion to the time and intensity of exposure to excitation light.
- For flow cytometry
- a. In the bicolor protocol, measure red fluorescence of PI at >620 nm using linear amplification.
 - b. In both flow cytometry protocols, measure FITC fluorescence as a green signal (530 nm peak fluorescence) by the FL1 detector through a band pass filter (530 +/- 15 nm) using logarithmic amplification.
 - c. In the triple-labeling protocol, measure R-phycoerythrin as an orange signal (575 nm peak fluorescence) by the FL2 detector through a band pass filter (585 +/-21 nm) using logarithmic amplification.
 - d. In the tricolor protocol, measure Cy-Chrom as a violet signal (peak fluorescence 670 nm) by the FL3 detector through a long pass filter (>650 nm) using logarithmic amplification.

TECH NOTE #7: Containers

- Wash and solvent exchange steps are best performed in coplin jars.
- A humidified chamber is required for the incubation steps. One can be constructed as follows using a clear plastic tray with a lid. Soak several paper towels in water and place them at the bottom of the tray. Place two pipettes across the towels. Place the slides across pipettes. Put the lid on top and place the chamber in a 37°C incubator.

TECH NOTE #8: Plastic coverslips


- Plastic coverslips can be used to assure that a constant volume of solution is applied per unit of specimen area. However, their handling time slows down the protocol.
- Each square centimeter of plastic coverslip will require the volume of reagent indicated in Table 3 so that the reagent volume applied per unit of

tissue area can be held constant. The surface to be covered is always equal to the area of the plastic coverslip, not the area of the specimen.

- Plastic coverslips may be trimmed to any desired size and shape. The kit's yield of specimens will be reduced if larger than standard coverslips are used.
- Plastic coverslips can be used during the incubation steps with the following reagents: WORKING STRENGTH TdT, and the ANTI-DIGOXIGENIN ANTIBODY.
- A basic coverslip method is described as follows:

To make a pair of "standard area" (~ 5 cm²) specimen coverslips, cut a plastic coverslip (provided) into two equal halves, and fold up a 1 cm handling tab across the width, then crease sharply (See Figure 3).

Figure 3: Unit TdT Dilution and Plastic Coverslips Use



- Drain one slide for approximately 10 seconds, and then tap off drops on a paper towel on the benchtop. Blot back and sides of the slide with a folded wipe. Carefully blot the area around the tissue section or cells, or else vacuum up solution using a pipette attached to an aspirator vacuum.
- Apply reagent solution to one end of the area to be covered, using a dropper bottle or pipette as required.
- Grasp the plastic coverslip by the handling tab and touch its opposite end to the droplet of reagent on the slide. Slightly arching the coverslip, roll it slowly downward, causing the solution to spread by capillary action. If solution does not spread evenly, tilt the slide until the flow reaches all edges.

- Apply plastic coverslips to microscope slides so as to minimize trapped air bubbles, which may cause variable enzyme reaction or detection.
- Place the slide across the pipettes, face-up and level, inside the humidified chamber. The slide edges should not touch anything so as to prevent drainage of the reagent.

TECH NOTE #9: Controls

- Positive controls
 - a. In the normal female rodent mammary gland, extensive apoptosis occurs 3-5 days after weaning of rat pups (36). Sections of this tissue mounted on slides may be purchased (S7115). Typically, 1-2% of the total number of cells on the slide are apoptotic. For biological positive controls, programmed cell death can be induced in young adult rat thymic lymphocytes by dexamethasone (3, 13). In normal rodent testis, apoptotic spermatogonia spontaneously occur in the seminiferous tubules (2).
 - b. A positive control sample can be prepared from any tissue sample by treating with DNase I by (3, 13), as follows.
 1. Pretreat section with DN Buffer (30 mM Trizma base, pH 7.2, 4 mM MgCl₂, 0.1 mM DTT) at room temp. for 5 minutes.
 2. Dissolve DNase I in DN Buffer to a final concentration of 1.0-0.1 µg/mL (specific activity is 10,000 U/mL - 1,000 U/mL).
 3. Apply DNase solution and incubate for 10 minutes at room temp.
 4. Rinse with 5 changes of dH₂O for 3 minutes each change.
- Chemicon recommends using DNase I from Sigma (D7291) or Worthington Biochemical (LS06333). As the consistency and prior processing of tissues will differ, testing a range of conditions including proteinase K digestion is recommended.
- Negative Controls
 - a. A negative control or sham staining can be performed without active TdT but including proteinase K digestion to control for nonspecific incorporation of nucleotides or for nonspecific binding of enzyme-conjugate. Water or Equilibration Buffer can be substituted for the volume of TdT ENZYME reagent.
 - b. Inactive WORKING STRENGTH TdT can be prepared by adding to the regular TdT mixture, a 5% (v:v) dilution from the bottle of Stop/

Wash Buffer concentrate, to chelate the divalent cationic enzyme cofactor.

- c. Simple application of DAB substrate to an unreacted but rehydrated tissue indicates whether possible endogenous peroxidase activity is present or has been properly quenched by the use of hydrogen peroxide. Similarly, the level of tissue autofluorescence can be seen in unreacted tissue.

TECH NOTE #10: Additional pretreatment procedures

- Besides protease, there are two other possible pretreatments for exposing the DNA.
- In the heating method, the slide is placed in 10 mM citrate buffer, pH 3.0 - 6.0, in a coplin jar, and gently boiled for 3-5 cycles of 3 minutes each in a microwave oven (28b, 37). Refill with fresh buffer between cycles. Do not let the sample dry out. A pressure cooker or an autoclave can be used instead of a microwave. Let the solution sit on the bench until it reaches a warm but not room temp. before proceeding.
- In the detergent pretreatment method, 0.5% TRITON X-100 can be applied for 10 minutes. (41).

TECH NOTE #11: Sample handling

- Do not let the specimen go dry by evaporation when changing solutions. Remove the slides from the final wash and tap off excess water, then blot or aspirate around the section, and promptly apply the next reagent. If there are many samples to be processed, slides can be treated at fixed time intervals (e.g. every 20-30 seconds) and immediately placed in a humid chamber. Incubations can then be terminated at similar intervals to maintain a constant incubation time.

TECH NOTE #12: Use of xylene

- Keep the xylene used for de-waxing paraffin tissues separate from xylene used for the last dehydration step before specimen mounting. Keep organic solvents tightly capped when not in use.

TECH NOTE #13: Optional stopping points

- There are several optional stopping points for temporary storage during sample processing. These are:
In the microscopy protocols:

- a. Slides may be left in EQUILIBRATION BUFFER or water for up to 60 minutes at 4°C to room temp.
- b. After incubating in working strength TDT ENZYME, slides can be washed for 5 minutes in STOP-WASH SOLUTION, and then immersed in 70% EtOH in a coplin jar and stored at -20°C for at least 3 days. Before continuing with the protocols, samples should be washed with three changes of PBS for 2 minutes per change.

In the flow cytometry protocols:

- a. After placing the cells in 70% ethanol, they can be stored at -20°C for at least 3 months.
- b. After PI is added, the tube containing the cells can be wrapped in foil and stored at 4°C for 2-3 days.

TECH NOTE #14: Morphological confirmation of apoptosis

- To confirm morphological apoptosis, a sample of unsorted live positive cells can be checked in a phase contrast microscope. Apoptotic cells appear phase-dark and have pyknotic nuclei. Using a fluorescence microscope, live cells can be stained for phosphatidylserine externalization on membrane blebs with the Annexin V FITC protein; or they can be stained to examine for marginated or segmented chromatin morphology with a membrane permeant DNA-binding dye such as Hoechst 33342 (10).

TECH NOTE #15: Fluorescent counterstains

- PI or DAPI staining intensity, as visualized by microscopy, is affected by variations in these factors: the tissue type, the fixation method (type, concentration, freshness and time), tissue pretreatments (proteinase or other), the stain concentration, the light filter used, and photobleaching during imaging. The optimal counterstain concentration will result in fluorescence intensity nearly equal to that of the primary stain. In addition, the fluorescence signal per cell may be less intense when more concentrated samples are tested (i.e. more cells/mL) by flow cytometry.

TECH NOTE #16: Fixation using plastic supports

- If adherent cells do not remain on the support during the procedure, the cells may be air dried onto the support prior to fixation in 1% PARAFORMALDEHYDE. However, it is important to remember that apoptosis in adherent cell cultures can result in detachment from the substrate.

Table 4: ApopTag[®] Tunel Apoptosis Detection Kit

Cat #	Product	Quantity
S7100	ApopTag [®] Peroxidase <i>In Situ</i> Apoptosis Detection Kit	40 Assays
S7101	ApopTag [®] Plus Peroxidase <i>In Situ</i> Apoptosis Detection Kit	40 Assays
S7110	ApopTag [®] Fluorescein <i>In Situ</i> Apoptosis Detection Kit	40 Assays
S7111	ApopTag [®] Plus Fluorescein <i>In Situ</i> Apoptosis Detection Kit	40 Assays
S7160	ApopTag [®] Fluorescein Direct <i>In Situ</i> Apoptosis Detection Kit	40 Assays

Related Products

Table 5: Apoptosis Reagents

Cat #	Product	Quantity
S7114	Antifade Solution	1 mL
S7106	ApopTag [®] Equilibration Buffer	15 mL
S7115	ApopTag [®] Positive Control Slides	5 slides
S7105	ApopTag [®] Reaction Buffer	1 mL
S7108	ApopTag [®] Stop/Wash Buffer	20 mL
S7107	ApopTag [®] TdT Enzyme	300 mL
S7113	DAPI/Antifade Solution	1 mL
S7112	Propidium Iodide/Antifade Solution	1 mL
S7109	Propidium Iodide Solution	1 mL

Positive Control Slides are supplied in the ApopTag[®] Plus Peroxidase *In Situ* Apoptosis Detection Kit (S7101), ApopTag[®] Plus Fluorescein *In Situ* Apoptosis Detection Kit (S7111), and by the package (S7115). The slides contain unstained rat mammary glands obtained at the fourth day after weaning (36), which were fixed for 18 hours in 10% neutral buffered formalin. After embedding in paraffin, 5 micron thick sections were cut from the middle of the tissue and mounted on silanized slides.

Table 6: Caspase Assays

Cat #	Product	# of Tests
APT403	CaspaTag™ Caspase 3 <i>In Situ</i> Assay Kit, Fluorescein	100 tests
APT400	CaspaTag™ Pan-Caspase <i>In Situ</i> Assay Kit, Fluorescein	100 tests
APT500	CaspaTag™ Pan-Caspase <i>In Situ</i> Assay Kit, Sulforhodamine	100 tests
APT503	CaspaTag™ Caspase 3 <i>In Situ</i> Assay Kit, Sulforhodamine	100 tests

Table 7: DNA Fragmentation Analysis (Ligation)

Cat #	Product	Quantity
S7200	ApopTag® Peroxidase <i>In Situ</i> Oligo Ligation (ISOL) Apoptosis Detection Kit	40 Assays

Table 8: Mitochondrial Membrane Permeabilization

Cat #	Product	Quantity
APT142	MitoLight® Mitochondrial Apoptosis Detection Kit	25 Assays

IV. REFERENCES

Internet Sites

Chemicon Corporation: www.chemicon.com

APOPTOSIS Online: The Apoptosis Information & Communication Center at www.apopnet.com

Purdue Cytometry Mailing List:
www.cyto.purdue.edu/hmarchive/Cytometry/index.html

PubMed: www.ncbi.nlm.nih.gov/pubmed

Publications Cited in Manual

1. Ahuja, H.S., W. James and Z. Zaheri. (1997) Rescue of the limb deformity in Hammertoe mutant mice by retinoic acid-induced cell death. *Develop. Dynamics* 208:466-481.
2. Allen, D.J., S.A. Roberts, and B.V. Harmon. (1993) Spontaneous spermatogonial apoptosis shows three distinct morphological phases and no circadian rhythm in the rat. *Cell Proliferation* 25: 241-250.
3. Arends, M.J., R.G. Morris and A.H. Wyllie. (1990) Apoptosis: The role of the endonuclease. *Amer. J. Pathol.* 136: 593-608.
4. Attanasio, A. and D. Schiffer. (1995) Ultrastructural detection of DNA strand breaks by *in situ* end-labelling techniques. *J. Pathol.* 176:27-35.
5. Brown, D.G., X.M. Sun and G.M. Cohen. (1993) Dexamethasone-induced apoptosis involves cleavage of DNA to large fragments prior to internucleosomal fragmentation. *J. Biol. Chem.* 268: 3037-3039.
6. Bursch, W., L. Kleine and M. Tenniswood. (1990) Determination of the length of the histological stages of apoptosis in normal liver and altered hepatic foci of rats. *Carcinogenesis* (London) 11: 847-853.
7. Bursch, W., S. Paffe, B. Putz, G. Barthel and R. Schulte-Hermann. (1990) Biochemistry of cell death by apoptosis. *Biochem. Cell Biol.* 68: 1071-1074.
8. Chapman, R.S., C.M. Chresta, A.A. Herberg, H.M. Beere, S. Heer, A.D. Whetton, J.A. Hickman and C. Dive. (1995) Further characterization of the

in situ terminal deoxynucleotidyl transferase (TdT) assay for the flow cytometric analysis of apoptosis in drug resistant and drug sensitive leukemia cells. *Cytometry* 20:245-256.

9. Davidson, F.D., M. Groves and F. Scaravilli. (1995) The effects of formalin fixation on the detection of apoptosis in human brain by *in situ* end-labeling of DNA. *Histochem. J.* 27:983-988.
10. Darzynkiewicz, Z., X. Li and J. Gong. (1994) Assays of Cell Viability. Discrimination of cells dying in apoptosis. Methods, Chapter 2, Section VII in *Cell Biology: Flow Cytometry*, 2nd edition, Darzynkiewicz, Z., Crissman, H.A. and Robinson, J.R., eds., Academic Press.
11. Darzynkiewicz, Z., G. Juan, X. Li, W. Gorczyca, T. Murakami and F. Traganos. (1997) Cytometry in cell necrobiology: Analysis of apoptosis and accidental cell death (necrosis). *Cytometry* 27:1-20.
12. Eldadah, B.A., A.G. Yakovlev and A.I. Faden. (1996) A new approach for the electrophoretic detection of apoptosis. *Nucl. Acids Res.* 24:4092-4093.
13. Gavrieli, Y., Y. Sherman, and S.A. Ben-Sasson. (1992) Identification of programmed cell death *in situ* via specific labeling of nuclear DNA fragmentation. *J. Cell Biol.* 119: 493-501.
14. Gold, R. (1994) Differentiation between cellular apoptosis and necrosis by the combined use of *in situ* tailing and nick translation techniques. *Lab Invest.* 71: 219-225.
15. Gong, J., F. Traganos and Z. Darzynkiewicz. (1994) A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. *Anal. Biochem.* 218:314-319.
16. Gorczyca, W., S. Bruno, R.J. Darzynkiewicz, J. Gong and Z. Darzynkiewicz. (1992) DNA strand breaks occurring during apoptosis: Their early *in situ* detection by terminal deoxynucleotidyl transferase and nick translation assays and prevention by serine protease inhibitors. *Int. J. Oncol.* 1: 639-648.
17. Gorczyca, W., J. Gong and Z. Darzynkiewicz. (1993) Detection of DNA strand breaks in individual apoptotic cells by the *in situ* terminal deoxynucleotidyl transferase and nick translation assays. *Cancer Res.* 53: 1-7.
18. Halicka, H.D., K. Seiter, E.J. Feldman, F. Traganos, A. Mittleman, T. Ahmed and Z. Darzynkiewicz. (1997) Cell cycle specificity of apoptosis during treatment of leukemias. *Apoptosis* 2:25-39.

19. Kerr, J.F.R. and B.V. Harmon. (1991) Definition and incidence of apoptosis: An historical perspective. *Apoptosis: Molecular basis of Cell Death*, chapt. 1, Cold Spring Harbor Laboratory Press, pp.5-29.
20. Kockx, M.M. (1996) Biotin- or digoxigenin-conjugated nucleotides bind to matrix vesicles in atherosclerotic plaques. *Am. J. Pathol.* 148:1771-1777.
21. Kyprianou, N. and J. Isaacs. (1988) Activation of programmed cell death in the rat ventral prostate after castration. *Endocrin.* 122: 552-562.
22. Li, W., W.M. James, F. Traganos and Z. Darzynkiewicz. (1995) Application of biotin, digoxigenin or fluorescein conjugated deoxynucleotides to label DNA strand breaks for analysis of cell proliferation and apoptosis using flow cytometry. *Biotechnic and Histochem.* 70:234-242.
23. Li, X., M.R. Melamed and Z. Darzynkiewicz. (1996) Detection of apoptosis and DNA replication by differential labeling of DNA strand breaks with fluorochromes of different color. *Exp. Cell Res.* 222:28-37.
24. Majno, G. and I. Joris. (1995) Apoptosis, oncosis and necrosis, an overview of cell death. *Am. J. Pathol.* 146:3-15.
25. McGahon, A., R. Bissonnette, M. Schmitt, K.M. Cotter, D.R. Green and T.G. Cotter. (1994) BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. *Blood* 83: 1179-1187.
26. Migheli, A.M., A. Attanasio and D. Schiffer. (1995) Ultrastructural detection of DNA strand breaks in apoptotic neural cells by *in situ* end-labeling techniques. *J. Pathol.* 176:27-35.
27. Mundle, S., A. Iftikhar, V. Shetty, S. Dameron, V. Wright Quinones, B. Marcus, J. Loew, S. Gregory and A. Raza. (1994) Novel *in situ* double-labeling for simultaneous detection of proliferation and apoptosis. *J. Histochem. Cytochem.* 42:1533-1537.
- 28a. Negoescu, A., P. Lorimier, F. Labat Moleur, C. Drouet, C. Robert, C. Guillermet, C. Brambilla and E. Brambilla. (1996) *In situ* apoptotic cell labeling by the TUNEL method: improvement and evaluation on cell populations. *J. Histochem. Cytochem.* 44 (9) 959-968.

- 28b. Labat Moleur, F., C. Guillermet, P. Lorimier, C. Robert, S. Lantuejoul, E. Brambilla and A. Negoescu. (1998) TUNEL apoptotic cell detection in tissue sections: critical evaluation and improvement. *J. Histochem. Cytochem.* 46:327-334.
29. Perry, S.W., L.G. Epstein and H.A. Gelbard. (1997) Simultaneous *in situ* detection of apoptosis and necrosis in monolayer cultures by TUNEL and trypan blue staining. *BioTechniques* 22:1102-1106.
30. Rösl, F. (1992) A rapid and simple method for detection of apoptosis in human cells. *Nucleic Acids Res.* 20: 5243.
31. Schmitz, G.G., T. Walter, R. Seibl and C. Kessler. (1991) Nonradioactive labeling of oligonucleotides *in vitro* with the hapten digoxigenin by tailing with terminal transferase. *Anal. Biochem.* 192: 222-231.
32. Sgonc, R. and G. Wick. (1994) Methods for the detection of apoptosis. *Int. Arch. Allergy Immunol.* 105: 327.
33. Sgonc, R., G. Boeck, H. Dietrich, J. Gruber, H. Recheis and G. Wick. (1994) Simultaneous determination of cell surface antigens and apoptosis. *Trends in Genetics* 10:41-42.
34. Smith, S. and M. Cartwright. (1997) Spatial visualization of apoptosis using a wholemount *in situ* DNA end-labeling technique. *Biotechniques* 22:832-834.
35. Staley, K., A.H. Blaschke and J. Chun. (1997) Apoptotic DNA fragmentation is detected by a semi-quantitative ligation-mediated PCR of blunt DNA ends. *Cell Death Different.* 4:66-75.
36. Strange, R., R.R. Friis, L.T. Bemis and F.J. Geske. (1995) Programmed cell death during mammary gland involution. Chapt. 15 of Cell Death, *Methods in Cell Biol.* 46:355-366, pub. by Academic Press.
37. Strater, J., A.R. Gunthert, S. Bruderlein and P. Moller. (1995) Microwave irradiation of paraffin-embedded tissue sensitizes the TUNEL method for *in situ* detection of apoptotic cells. *Histochem. Cell Biol.* 103:157-160.
38. Thiry, M. (1992) Highly sensitive immunodetection of DNA on sections with exogenous terminal deoxynucleotidyl transferase and non-isotopic nucleotide analogs. *J. Histochem. Cytochem.* 40: 411-419.
39. Thompson, H.J., R. Strange and P.J. Schedin. (1992) Apoptosis in the genesis and prevention of cancer. *Cancer Epidem. Biomarkers and Prevention* 1: 597-602.

40. Tilly, J.L., K.I. Kowalski, A.L. Johnson and A.J. Hsueh. (1991) Involvement of apoptosis in ovarian follicular atresia and postovulatory regression. *Endocrinology* 129: 2799-2801.
41. Tornusciolo, D.R., R.E. Schmidt and K.A. Roth. (1995) Simultaneous detection of TdT mediated dUTP-biotin nick end labelling (TUNEL)-positive cells and multiple immunohistochemical markers in single tissue sections. *BioTechniques* 19:800-805.
42. Trump, B.F., I.K. Borezesky, S.H. Chang and P.C. Phelps. (1997) The pathways of cell death: Oncosis, apoptosis and necrosis. *Toxicol. Pathol.* 25:82-8.
43. Walker, P.R., L. Kokileva, J. LeBlanc and M. Sikorska. (1993) Detection of the initial stages of DNA fragmentation in apoptosis. *Biotechniques* 15: 1032-1047.
44. Walker, P.R., V.M. Weaver, B. Lach, J. LeBlanc and M. Sikorska. (1994) Endonuclease activities associated with high molecular weight and internucleosomal DNA fragmentation in apoptosis. *Exp. Cell. Res.* 213: 100-106.
45. White, K., M.E. Grether, J.M. Abrams, L. Young, K. Farrell and H. Steller. (1994) Genetic control of programmed cell death in *Drosophila*, n.b. Figure 9 & Note 45. *Science* 264:677-683.
46. Wijsman, J.H., R.R. Jonker, R. Keijzer, C.J.H. Van De Velde, C.J. Cornelisse and J.H. Van Dierendonck. (1993) A new method to detect apoptosis in paraffin sections: *in situ* end-labeling of fragmented DNA. *J. Histochem. Cytochem.* 41: 7-12.

Publications Citing ApopTag® Kits

- Alvarez, M. E., R. I. Pennell, P-J. Meijer, A. Ishikawa, R. A. Dixon, and C. Lamb. (1998) Reactive Oxygen Intermediates Mediate a Systemic Signal Network in the Establishment of Plant Immunity. *Cell* 92:773-784.
- Ambrosini, G., C. Adida, G. Sirugo, and D. C. Altieri. (1998) Induction of Apoptosis and Inhibition of Cell Proliferation by survivin Gene Targeting. *J. Biol. Chem.* 273:11177-11182.
- Arguello, F., M. Alexander, J. A. Sterry, G. Tudor, E. M. Smith, N. T. Kalavar, Jr. Greene, J.F., W. Koss, C. D. Morgan, S. F. Stinson, T. J. Siford, W. G. Alvord, R. L. Klabansky, and E. A. Sausville. (1998) Flavopiridol Induces

Apoptosis of Normal Lymphoid Cells, Causes Immunosuppression, and Has Potent Antitumor Activity In Vivo Against Human Leukemia and Lymphoma Xenografts. *Blood* 91:2482-2490.

Bossy-Wetzel, E., D. D. Newmeyer, and D. R. Green. (1998) Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. *The EMBO Journal* 17:37-49.

Britsch, S., L. Li, S. Kirchhoff, F. Theuring, V. Brinkmann, C. Birchmeier, and D. Riethmacher. (1998) The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system. *Genes & Development* 12:1825-1836.

Caamano, J. H., C. A. Rizzo, S. K. Durham, D. S. Barton, C. Raventos-Suarez, C. M. Snapper, and R. Bravo. (1998) Nuclear Factor (NF)-kappaB2 (p100/p52) Is Required for Normal Splenic Microarchitecture and B Cell-mediated Immune Responses. *J. Exp. Med.* 187:185-196.

Carmeliet, P., Y. Dor, J-M. Herbert, D. Fukumura, K. Brusselmans, M. Dewerchin, M. Neeman, F. Bono, R. Abramovitch, P. Maxwell, C. J. Koch, P. Ratcliffe, L. Moons, R. K. Jain, D. Collen, and E. Keshet. (1998) Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. *Nature* 394:485-490.

Carrasco, D., J. Cheng, A. Lewin, G. Warr, H. Yang, C. Rizzo, F. Rosas, C. Snapper, and R. Bravo. (1998) Multiple Hemopoietic Defects and Lymphoid Hyperplasia in Mice Lacking the Transcriptional Activation Domain of the c-Rel Protein. *J. Exp. Med.* 187:973-984.

Celli, G., W. J. LaRochelle, S. Mackem, R. Sharp, and G. Merlino. (1998) Soluble dominant-negative receptor uncovers essential roles for fibroblast growth factors in multi-organ induction and patterning. *The EMBO Journal* 17:1642-1655.

Cheng, Y., M. Deshmukh, A. D'Costa, J. A. Demaro, J. M. Gidday, A. Shah, Y. Sun, M. F. Jacquin, Jr. Johnson, E.M., and D. M. Holtzman. (1998) Caspase Inhibitor Affords Neuroprotection with Delayed Administration in a Rat Model of Neonatal Hypoxic-Ischemic Brain Injury. *J. Clin. Invest.* 101:1992-1999.

Clifton, D. R., R. A. Goss, S. K. Sahni, D. van Antwerp, R. B. Baggs, V. J. Marder, D. J. Silverman, and L. A. Sporn. (1998) NF-kappaB-dependent inhibition of apoptosis is essential for host cell survival during Rickettsia rickettsii infection. *PNAS, USA* 95:4646-4651.

- Cosyns, M., S. Tsirkin, M. Jones, R. Flavell, H. Kikutani, and A. R. Hayward. (1998) Requirement for CD40-CD40 Ligand Interaction for Elimination of *Cryptosporidium parvum* from Mice. *Infection and Immunity* 66:603-607.
- Dahl, J., A. Jurczak, L. A. Cheng, D. C. Baker, and T. L. Benjamin. (1998) Evidence of a Role for Phosphatidylinositol 3-Kinase Activation in the Blocking of Apoptosis by Polyomavirus Middle T Antigen. *J. Virol.* 72:3221-3226.
- Davis, I. C., M. Girard, and P. N. Fultz. (1998) Loss of CD4+ T Cells in Human Immunodeficiency Virus Type 1-Infected Chimpanzees Is Associated with Increased Lymphocyte Apoptosis. *J. Virol.* 72:4623-4632.
- De, S. K., C. N. S. Venkateshan, P. Seth, D. C. Gajdusek, and C. J. Gibbs, Jr. (1998) Adenovirus-Mediated Human Immunodeficiency Virus-1 Nef Expression in Human Monocytes/Macrophages and Effect of Nef on Downmodulation of Fc γ Receptors and Expression of Monokines. *Blood* 91:2108-2117.
- Dockrell, D. H., A. D. Badley, J. S. Villacian, C. J. Heppelmann, A. Algeciras, S. Ziesmer, H. Yagita, D. H. Lynch, P. C. Roche, P. J. Leibson, and C. V. Paya. (1998) The Expression of Fas Ligand by Macrophages and its Upregulation by Human Immunodeficiency Virus Infection. *J. Clin. Invest.* 101:2394-2405.
- Dugyala, R. R., R. P. Sharma, M. Tsunoda, and R. T. Riley. (1998) Tumor Necrosis Factor- α as a Contributor in Fumonisin B1 Toxicity. *JPET* 285:317-324.
- Eichmuller, S., C. van der Veen, I. Moll, B. Hermes, U. Hofmann, S. Muller-Rover, and R. Paus. (1998) Clusters of Perifollicular Macrophages in Normal Murine Skin: Physiological Degeneration of Selected Hair Follicles by Programmed Organ Deletion. *J. Histochem. Cytochem.* 46:361-370.
- Faraldo, M. M., M-A. Deugnier, M. Lukashev, J. P. Thiery, and M. A. Glukhova. (1998) Perturbation of β 1-integrin function alters the development of murine mammary gland. *The EMBO Journal* 17:2139-2147.
- Ferrari, M. B., K. Ribbeck, Jr. Hagler, D.J., and N. C. Spitzer. (1998) A Calcium Signaling Cascade Essential for Myosin Thick Filament Assembly in Xenopus Myocytes. *J. Cell Biol.* 141:1349-1356.
- Ganiatsas, S., L. Kwee, Y. Fujiwara, A. Perkins, T. Ideda, M. A. Labow, and L. I. Zon. (1998) SEK1 deficiency reveals mitogen-activated protein kinase cascade crossregulation and leads to abnormal hepatogenesis. *PNAS, USA* 95:6881-6886.

- Hande, S., E. Notidis, and T. Manser. (1998) Bcl-2 Obstructs Negative Selection of Autoreactive, Hypermutated Antibody V Regions during Memory B Cell Development. *Immunity* 8:189-198.
- Ito, Y. and Y. Otsuki. (1998) Localization of Apoptotic Cells in the Human Epidermis by an *In situ* DNA Nick End-labeling Method Using Confocal Reflectant Laser Microscopy. *J. Histochem. Cytochem.* 46:783-786.
- Itoh, M., H. Hotta, and M. Homma. (1998) Increased Induction of Apoptosis by a Sendai Virus Mutant Is Associated with Attenuation of Mouse Pathogenicity. *J. Virol.* 72:2927-2934.
- Jiang, R., Y. Lan, H. D. Chapman, C. Shawber, C. R. Norton, D. V. Serreze, G. Weinmaster, and T. Gridley. (1998) Defects in limb, craniofacial, and thymic development in Jagged2 mutant mice. *Genes & Development* 12:1046-1057.
- Kemeny, M. M., G. I. Botchkina, M. Ochani, M. Bianchi, C. Urmacher, and K. J. Tracey. (1998) The tetravalent guanylhydrazone CNI-1493 blocks the toxic effects of interleukin-2 without diminishing antitumor efficacy. *PNAS, USA* 95:4561-4566.
- Kubo, S., M. Sun, M. Miyahara, K. Umeyama, K. Urakami, T. Yamamoto, C. Jakobs, I. Matsuda, and F. Endo. (1998) Hepatocyte injury in tyrosinemia type 1 is induced by fumarylacetoacetate and is inhibited by caspase inhibitors. *PNAS, USA* 95:9552-9557.
- Labat-Moleur, F., C. Guillermet, P. Lorimier, C. Robert, S. Lantuejoul, E. Brambilla, and A. Negoescu. (1998) TUNEL Apoptotic Cell Detection in Tissue Sections: Critical Evaluation and Improvement. *J. Histochem. Cytochem.* 46:327-334.
- Liu, J-L., Y. Ye, L. F. Lee, and H-J. Kung. (1998) Transforming Potential of the Herpesvirus Oncoprotein MEQ: Morphological Transformation, Serum-Independent Growth, and Inhibition of Apoptosis. *J. Virol.* 72:388-395.
- Maina, F., M. C. Hilton, R. Andres, S. Wyatt, T. Klein, and A. M. Davies. (1998) Multiple Roles for Hepatocyte Growth Factor in Sympathetic Neuron Development. *Neuron* 20:835-846.
- Matter, M. L., Z. Zhang, C. Nordstedt, and E. Ruoslahti. (1998) The alpha5beta1 Integrin Mediates Elimination of Amyloid-beta Peptide and Protects Against Apoptosis. *J. Cell Biol.* 141:1019-1030.
- Maulik, N., V. E. Kagan, V. A. Tyurin, and D. K. Das. (1998) Redistribution of phosphatidylethanolamine and phosphatidylserine precedes reperfusion-induced apoptosis. *Am. J. Physiol.* 274:H242-H248.

- Megyesi, J., R. L. Safirstein, and P. M. Price. (1998) Induction of p21WAF1/CIP1/SDI1 in Kidney Tubule Cells Affects the Course of Cisplatin-induced Acute Renal Failure. *J. Clin. Invest.* 101:777-782.
- Motoyama, S., Y. Minamiya, S. Saito, R. Saito, I. Matsuzaki, S. Abo, H. Inaba, K. Enomoto, and M. Kitamura. (1998) Hydrogen Peroxide Derived From Hepatocytes Induces Sinusoidal Endothelial Cell Apoptosis in Perfused Hypoxic Rat Liver. *Gastroenterology* 114:153-163.
- Noda, T., R. Iwakiri, K. Fujimoto, S. Matsuo, and T. Y. Aw. (1998) Programmed cell death induced by ischemia-reperfusion in rat intestinal mucosa. *Am. J. Physiol.* 274:G270-G276.
- O'Reilly, M. A., R. J. Staversky, B. R. Stripp, and J. N. Finkelstein. (1998) Exposure to Hyperoxia Induces p53 Expression in Mouse Lung Epithelium. *Am. J. Respir. Cell. Mol. Biol.* 18:43-50.
- Parsadanian, A. S., Y. Cheng, C. R. Keller-Peck, D. M. Holtzman, and W. D. Snider. (1998) Bcl-xL is an Antiapoptotic Regulator for Postnatal CNS Neurons. *J. Neurosci.* 18:1009-1019.
- Pierce, A. M., I. B. Gimenez-Conti, R. Schneider-Broussard, L. A. Martinez, C. J. Conti, and D. G. Johnson. (1998) Increased E2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53. *PNAS, USA* 95:8858-8863.
- Qin, Z-H., Y. Wang, M. Nakai, and T. N. Chase. (1998) Nuclear Factor-kappaB Contributes to Excitotoxin-Induced Apoptosis in Rat Striatum. *Molecular Pharmacology* 53:33-42.
- Rodrigues, C. M. P., G. Fan, X. Ma, B. T. Kren, and C. J. Steer. (1998) A Novel Role for Ursodeoxycholic Acid in Inhibiting Apoptosis by Modulating Mitochondrial Membrane Perturbation. *J. Clin. Invest.* 101:2790-2799.
- Romagnani, P., F. Annunziato, R. Manetti, C. Mavilia, L. Lasagni, C. Manuelli, G. B. Vannelli, V. Vanini, E. Maggi, C. Pupilli, and S. Romagnani. (1998) High CD30 Ligand Expression by Epithelial Cells and Hassal's Corpuscles in the Medulla of Human Thymus. *Blood* 91:3323-3332.
- Sakanaka, M., T-C. Wen, S. Matsuda, S. Masuda, E. Morishita, M. Nagao, and R. Sasaki. (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. *PNAS, USA* 95:4635-4640.
- Sawaoka, H., S. Kawano, S. Tsuji, M. Tsuji, E. S. Gunawan, Y. Takei, K. Nagano, and M. Hori. (1998) Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. *Am. J. Physiol.* 274:G1061-G1067.

- Schneider, P., N. Holler, J-L. Bodmer, M. Hahne, K. Frei, A. Fontana, and J. Tschopp. (1998) Conversion of Membrane-bound Fas(CD95) Ligand to Its Soluble Form Is Associated with Downregulation of Its Proapoptotic Activity and Loss of Liver Toxicity. *J. Exp. Med.* 187:1205-1213.
- Selleri, C., J. P. Maciejewski, F. Pane, L. Luciano, A. M. Raiola, I. Mostarda, F. Salvatore, and B. Rotoli. (1998) Fas-Mediated Modulation of Bcr/Abl in Chronic Myelogenous Leukemia Results in Differential Effects on Apoptosis. *Blood* 92:981-989.
- Vendola, K. A., J. Zhou, O. O. Adesanya, S. J. Weil, and C. A. Bondy. (1998) Androgens Stimulate Early Stages of Follicular Growth in the Primate Ovary. *J. Clin. Invest.* 101:2622-2629.
- Vu, T. J., J. M. Shipley, G. Bergers, J. E. Berger, J. A. Helms, D. Hanahan, S. D. Shapiro, R. M. Senior, and Z. Werb. (1998) MMP-9/Gelatinase B Is a Key Regulator of Growth Plate Angiogenesis and Apoptosis of Hypertrophic Chondrocytes. *Cell* 93:411-422.
- Wadia, J. S., R. M. E. Chalmers-Redman, W. J. H. Ju, G. W. Carlile, J. L. Phillips, A. D. Fraser, and W. G. Tatton. (1998) Mitochondrial Membrane Potential and Nuclear Changes in Apoptosis Caused by Serum and Nerve Growth Factor Withdrawal: Time Course and Modification by (-)-Deprenyl. *J. Neurosci.* 18:932-947.
- Wang, H. and J. A. Keiser. (1998) Molecular characterization of rabbit CPP32 and its function in vascular smooth muscle cell apoptosis. *Am. J. Physiol.* 274:H1132-H1140.
- Webster, M. A., J. N. Hutchinson, M. J. Rauh, S. K. Muthuswamy, M. Anton, C. G. Tortorice, R. D. Cardiff, F. L. Graham, J. A. Hassell, and W. J. Muller. (1998) Requirement for Both Shc and Phosphatidylinositol 3' Kinase Signaling Pathways in Polyomavirus Middle T-Mediated Mammary Tumorigenesis. *Molecular and Cellular Biology* 18:2344-2359.
- White, F. A., C. R. Keller-Peck, C. M. Knudson, S. J. Korsmeyer, and W. D. Snider. (1998) Widespread Elimination of Naturally Occuring Neuronal Death in Bax-Deficient Mice. *J. Neurosci.* 18:1428-1439.
- Xu, J., C-H. Yeh, S. Chen, L. He, S. L. Sensi, L. M. T. Canzoniero, D. W. Choi, and C. Y. Hsu. (1998) Involvement of de Novo Ceramide Biosynthesis in Tumor Necrosis Factor-alpha/Cycloheximide-induced Cerebral Endothelial Cell Death. *J. Biol. Chem.* 273:16521-1652.

Disclaimers

All trademarks, unless otherwise noted, are the property of Serologicals Royalty Company or CHEMICON® International, Inc.

Warranty

EMD Millipore Corporation (“EMD Millipore”) warrants its products will meet their applicable published specifications when used in accordance with their applicable instructions for a period of one year from shipment of the products. **EMD MILLIPORE MAKES NO OTHER WARRANTY, EXPRESSED OR IMPLIED. THERE IS NO WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.** The warranty provided herein and the data, specifications and descriptions of EMD Millipore products appearing in EMD Millipore’s published catalogues and product literature may not be altered except by express written agreement signed by an officer of EMD Millipore. Representations, oral or written, which are inconsistent with this warranty or such publications are not authorized and if given, should not be relied upon.

In the event of a breach of the foregoing warranty, EMD Millipore Corporation’s sole obligation shall be to repair or replace, at its option, the applicable product or part thereof, provided the customer notifies EMD Millipore Corporation promptly of any such breach. If after exercising reasonable efforts, EMD Millipore Corporation is unable to repair or replace the product or part, then EDM Millipore shall refund to the Company all monies paid for such applicable Product. **EMD MILLIPORE CORPORATION SHALL NOT BE LIABLE FOR CONSEQUENTIAL, INCIDENTAL, SPECIAL OR ANY OTHER DAMAGES RESULTING FROM ECONOMIC LOSS OR PROPERTY DAMAGE SUSTAINED BY ANY COMPANY CUSTOMER FROM THE USE OF ITS PRODUCTS.**

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

(c) 2009 - 2013: Merck KGaA, Darmstadt. All rights reserved. No part of these works may be reproduced in any form without permission in writing

Cat No. S7165

January 2013
Revision E: 41608
